It’s not the right time to quit: BioXcel Therapeutics Inc (BTAI) Stock

Mizuho lowered the price target for the BioXcel Therapeutics Inc (NASDAQ:BTAI) stock from “a Buy” to “a Neutral”. The rating was released on August 15, 2023, according to finviz.

Historical Earnings Surprises and Revenue Forecasts

Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of -$1.72 during the last quarter as opposed to a consensus estimate of -$1.3, which indicates the company missed its estimate by -$0.42, which implies that the company surprised the market by -32.30%. It appears that the average earnings per share estimate for the current quarter (ending in Dec 2023) is -$0.91. This is an average of 8 analysts’ earnings, where the high earnings per share estimate is -$0.61 and the low earnings per share estimate is -$1.23. According to 7 analyst estimates, an average revenue estimate of $740k is projected for the current quarter with a high revenue estimate of $2M and a low estimate of $300k.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The latest trade, Performances and Moving Averages give us the following Picture

The firm’s stock price fluctuated -47.44% within the last five trades and -27.24% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -73.65% in the last 6 months and -58.77% was subtracted to its value over the previous 3 months. BTAI stock is trading at a margin of -36.32%, -37.58% and -76.77% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

As of the close of trading, BTAI deals in the Healthcare domain. The stock is trading -94.26 percent below its 52-week high and 2.09 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -85.7. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does BioXcel Therapeutics Inc’s Profitability and Valuation Ratios Tell Us About the Stock?

With regard to the profitability of the company, the operating margin is currently at -16036.72 percent and the profit margin is -17037.44 percent, and the company has reported a gross margin of 23.59 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.

The stock’s market cap achieved a total value of $58.36 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 47.07 that mirrors the cost to be found for sales by the market.

Is Insider Trading a Real Thing?

Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 30.90 percent of BioXcel Therapeutics Inc shares are owned by insiders, and 34.78 percent are held by financial institutions. Mehta Vimal, the CEO and President at BioXcel Therapeutics Inc (BTAI) has sold 30,000 shares of firm on Jun 16 at a price of $20.18 against the total amount of $0.61 million. In another inside trade, Mehta Vimal, CEO and President of BioXcel Therapeutics Inc (NASDAQ:BTAI) sold 30,000 shares of the firm on Jun 15 for a total worth of $0.65 million at a price of $21.54. An inside trade which took place on May 22, CEO and President of BioXcel Therapeutics Inc Mehta Vimal sold 6,500 shares of firm against total price of $0.17 million at the cost of $25.79 per share.

Most Popular

Related Posts